We investigated IL-17A, IFNγ and IL-4 expression by circulating CD4+T-lymphocyte subsets from 47 new-onset DMARD-naïve RA patients and 29 HCs (healthy controls) before starting MTX treatment and during the initial 6 months of treatment (Figure 1). This evidence concerns the gene CD4 and rheumatoid arthritis.